Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity

Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achieved Wegovy® (semaglutide 2.4 mg and 7.2 mg) clinical and real-world data exploring its role in managing menopausal symptoms, including weight gain and migraine, and lowering cardiovascular risk Data on next-generation obesity pipeline, including the advanced combined amylin and GLP-1 receptor analogues Bagsværd, Denmark, 28 April 2026 – Novo Nordisk will present new clinical data and real-world evidence at the European Congress on Obesity, 12–15 May in Istanbul, Turkey. The full data, 52 abstracts, span Wegovy® (semaglutide 2.4 mg), higher-dose Wegovy® (semaglutide 7.2 mg), Wegovy® pill (oral semaglutide 25 mg), and CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg), an investigational first-in-class combination of a GLP-1 receptor agonist and a long-acting amylin analogue.